Media releases

Latest news

07 Feb 2023

Idorsia announces financial results for 2022 – building momentum to become a leading mid-sized biopharmaceutical company

06 Feb 2023

Idorsia announces the results of REACT a Phase 3 study of clazosentan in patients following aneurysmal subarachnoid hemorrhage

09 Jan 2023

Idorsia presents at the 41st J.P. Morgan Healthcare Conference – Achievements in 2022 provide the foundation for our success in 2023

16 Nov 2022

Idorsia and Simcere enter into a licensing agreement for daridorexant in China

25 Oct 2022

Idorsia announces financial results for the first nine months of 2022 – QUVIVIQ becoming a global brand

03 Oct 2022

Idorsia Japan announces positive results with daridorexant in a Phase 3 study of Japanese patients with insomnia

27 Sep 2022

Idorsia secures additional cash by entering into a building sale and leaseback agreement

26 Jul 2022

Idorsia announces financial results for the first half 2022 – reaching commercial stage

23 May 2022

Positive Phase 3 study with aprocitentan demonstrates significant antihypertensive efficacy in patients with resistant hypertension

26 Apr 2022

Idorsia announces financial results for the first quarter 2022 – first product launched, second in the starting blocks

14 Apr 2022

Idorsia holds its Annual General Meeting of Shareholders

03 Mar 2022

Idorsia issues Notice of the 2022 Annual General Meeting of Shareholders

25 Feb 2022

QUVIVIQ (daridorexant) recommended for approval in Europe as a new treatment for adults with insomnia disorder

08 Feb 2022

Idorsia announces financial results for 2021 – 2022 to be a transformative year – Sustainable profitability expected in 2025

24 Jan 2022

Idorsia appoints Guy Braunstein to Chief Medical Officer and Alberto Gimona to Head of Global Clinical Development

20 Jan 2022

Idorsia receives Japanese PMDA approval of PIVLAZ (clazosentan sodium) 150 mg

10 Jan 2022

Idorsia receives US FDA approval of QUVIVIQ (daridorexant) 25 and 50 mg for the treatment of adults with insomnia

13 Dec 2021

Idorsia to further characterize lucerastat for the treatment of Fabry disease by continuing the open-label extension of the Phase 3 MODIFY study

01 Nov 2021

Idorsia to advance cenerimod into Phase 3 development for treatment of patients with systemic lupus erythematosus

27 Oct 2021

Johnson & Johnson partially converts its convertible loan

Ad hoc announcements pursuant to Art. 53 LR

Ad hoc announcements pursuant to Art. 53 LR have been classified from 2021 onwards. A full archive of press releases can be found under the "All" tab.